Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: September 26, 2005
Last updated: June 17, 2012
Last verified: October 2009

RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving pemetrexed disodium together with carboplatin works in treating patients with extensive-stage small cell lung cancer.

Condition Intervention Phase
Lung Cancer
Drug: carboplatin
Drug: pemetrexed disodium
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Proportion of confirmed-tumor response [ Designated as safety issue: No ]

Estimated Enrollment: 77
Study Start Date: February 2006
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Detailed Description:



  • Determine the complete and partial response rates in patients with previously untreated, extensive-stage small cell lung cancer treated with pemetrexed disodium and carboplatin.


  • Determine the toxicity of this regimen in these patients.
  • Determine, preliminarily, the survival of patients treated with this regimen.
  • Determine, preliminarily, the response rate in patients 70 years and older treated with this regimen.
  • Determine, preliminarily, the toxicity of this regimen in patients 70 years and older.

OUTLINE: This is a multicenter study. Patients are stratified according to age (< 70 years vs ≥ 70 years).

Patients receive pemetrexed disodium IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease in the CNS only may receive whole-brain radiotherapy and then continue chemotherapy after completion of whole-brain radiotherapy for up to 6 courses.

After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 4 years.

PROJECTED ACCRUAL: Approximately 77 patients at least 46 who are < 70 years of age and at least 24 who are ≥ 70 years of age) will be accrued for this study within 20-26 months.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed small cell lung cancer

    • Previously untreated disease
    • No mixed histology
  • Extensive-stage disease

    • Clinically significant effusions (e.g., symptomatic pleural effusion) must be drained prior to treatment
  • Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
  • No symptomatic, untreated, or uncontrolled CNS metastases

    • CNS metastases previously treated with whole-brain radiotherapy allowed



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • At least 12 weeks


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9.0 g/dL


  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN) OR
  • Direct bilirubin normal
  • ALT and AST ≤ 3 times ULN (5 times ULN if there is liver involvement)


  • Creatinine clearance ≥ 45 mL/min


  • No angina pectoris
  • No congestive heart failure within the past 3 months, unless ejection fraction > 40%
  • No cardiac arrhythmia
  • No myocardial infarction within the past 3 months
  • No hypertension, including labile hypertension


  • No interstitial pneumonia
  • No extensive and symptomatic interstitial fibrosis of the lung


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No history of poor compliance with antihypertensive medication
  • Able to take folic acid, cyanocobalamin (vitamin B_12) supplementation, or dexamethasone
  • No uncontrolled diabetes
  • No serious condition that would preclude study participation
  • No clinically significant infection
  • No significant traumatic injury
  • No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanoma skin cancer

    • Low-grade (Gleason score ≤ 6), localized prostate cancer allowed even if diagnosed < 5 years prior to study entry
  • No seizure disorder
  • No other severe and/or uncontrolled medical condition


Biologic therapy

  • No concurrent immunotherapy
  • No concurrent immunomodulating agents


  • No other concurrent chemotherapy

Endocrine therapy

  • No concurrent hormonal therapy


  • See Disease Characteristics
  • Prior palliative radiotherapy allowed

    • No prior palliative radiotherapy to the chest except for ≤ 3 fractions for superior vena cava syndrome
  • No concurrent radiotherapy


  • More than 4 weeks since prior major surgery* (i.e., laparotomy) or open biopsy
  • More than 2 weeks since prior minor surgery* NOTE: *Insertion of a vascular access device is not considered major or minor surgery


  • More than 4 weeks since prior investigational therapy
  • No concurrent Hypericum perforatum (St. John's wort)
  • No concurrent inducers or inhibitors of CYP3A4
  • No concurrent medications that are metabolized by CYP3A4
  • No aspirin dose ≥ 1.3 grams per day for ≥ 10 days prior to and after study treatment
  • No other concurrent cytostatic or cytotoxic agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00227565

  Show 148 Study Locations
Sponsors and Collaborators
North Central Cancer Treatment Group
Study Chair: James R. Jett, MD Mayo Clinic
Investigator: Albert M. Bernath, MD Geisinger Cancer Institute at Geisinger Health
Investigator: Julian Molina, MD, PhD Mayo Clinic
  More Information

Additional Information:
Jett JR, Bernath AM, Foster NR, et al.: Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study. [Abstract] J Clin Oncol 26 (Suppl 15): A-8066, 2008.

Responsible Party: Jan C. Buckner, North Central Cancer Treatment Group Identifier: NCT00227565     History of Changes
Other Study ID Numbers: CDR0000442866, NCCTG-N0423
Study First Received: September 26, 2005
Last Updated: June 17, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by National Cancer Institute (NCI):
extensive stage small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on July 01, 2015